Evidence map›Paper›PMID 34209360›Full record

ArticleLife (Basel, Switzerland)2021

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.

Danijel Sikic, Helge Taubert, Ralph M Wirtz, Johannes Breyer, Markus Eckstein, Veronika Weyerer, Jennifer Kubon, Philipp Erben, Christian Bolenz, Maximilian Burger and 4 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Danijel SikicDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Helge TaubertDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0002-9077-1727
Ralph M WirtzSTRATIFYER Molecular Pathology GmbH, 541713 Cologne, Germany.
Johannes BreyerCaritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Markus EcksteinComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Veronika WeyererComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.ORCID 0000-0001-5919-7651
Jennifer KubonDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Philipp ErbenDepartment of Urology and Urosurgery, University Medical Centre Mannheim, 68167 Mannheim, Germany.ORCID 0000-0002-8279-7636
Christian BolenzDepartment of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany.
Maximilian BurgerCaritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Arndt HartmannComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Bernd WullichDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Sven WachDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Bastian KeckDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Regensburg · DEHeidelberg University · DEUniversity Hospital Ulm · DE

Funding

Friedrich-Alexander-Universität Erlangen-Nürnberg ELAN 18-08-18-1-Sikic
6 · The paper itself

Abstract

The role of the androgen receptor (AR) in non-muscle-invasive bladder cancer (NMIBC) remains controversial. We retrospectively analyzed the mRNA expression of AR using RT-qPCR in 95 patients with high-risk NMIBC treated with a bladder-sparing approach and correlated AR with clinical data and recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). The mRNA expression of AR and KRT5, i.e., the basal-like subtype, was strongly correlated (rs = 0.456;

Indexed as

androgen receptorbladder cancerKRT20KRT5mRNANMIBCPCR

Identifiers

PMID34209360
PMCPMC8306811
OpenAlexW3175702518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.